Loading organizations...
Innerwell, a New York City-based mental health platform, provides at-home psychedelic-assisted therapy, including ketamine treatment, EMDR, psychiatry, and talk therapy for depression and anxiety. The company offers paid mental health services, now in-network with insurers such as Aetna, Anthem, Blue Shield California, Magellan, and Optum, covering over 22 million individuals. Innerwell secured $3 million in pre-seed funding in June 2022, led by Greycroft (Ellie Wheeler), with participation from Looking Glass, Max Ventures, and 645 Ventures (Aaron Holiday, Nnamdi Okike). Operating with an estimated 1-10 employees, Innerwell launched Innerwell Insights, an AI-driven behavioral coaching platform, in February 2024. Founded in 2021, Innerwell's leadership includes CEO Lisa Kennedy and co-founder Anthony Mangia. Its business model centers on offers paid mental health services, now in-network with insurers like Aetna, Anthem, Blue Shield California, Magellan, and Optum in select states.
Innerwell has raised $3.0M across 1 funding round.
Innerwell has raised $3.0M in total across 1 funding round.
Innerwell has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in May 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2022 | $3M Seed | — | 645 Ventures, Bennett Siegel, Accel, Accomplice VC, ACME Capital, Amity Ventures, Stuart Peterson, Balderton Capital, Color Capital, David Namdar, Cultivation Capital, Declaration Partners, Endeavor Venture Funds, Evolution Equity Partners, Flex Capital, Foundation Capital, Freestyle Capital, General Catalyst, ICONIQ Capital, Long Journey Ventures, M13, Recall Capital, Sapphire Ventures, The HIT Forge, TitletownTech, Tusk Venture Partners, Bruno Bowden, Daniel Gorfine, Frederic Kerrest, Gokul Rajaram, Jaime Schmidt, Jared Hyatt, SAM Kassoumeh, Troy Paredes | Announced |
Innerwell has raised $3.0M in total across 1 funding round.
Innerwell's investors include 645 Ventures, Bennett Siegel, Accel, Accomplice VC, ACME Capital, Amity Ventures, Stuart Peterson, Balderton Capital, Color Capital, David Namdar, Cultivation Capital, Declaration Partners.
# Innerwell: A Psychedelic Telehealth Platform
Innerwell is a telehealth platform specializing in ketamine-assisted psychotherapy (KAP) delivered virtually to patients in their homes.[1][2] The company emerged from stealth in 2025 with $3 million in pre-seed funding led by Greycroft, with participation from Looking Glass and Max Ventures.[1][2]
The company addresses a significant market opportunity: approximately 65 million Americans suffer from mental illness annually, yet access to evidence-based psychedelic-assisted therapies remains limited.[1][2] Innerwell's core offering combines licensed psychiatrists and psychotherapists working collaboratively to deliver ketamine-assisted psychotherapy in a virtual setting, supported by personalized digital care and behavioral health measurement tools.[1][2] The platform currently operates in multiple states including Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa, Minnesota, New Jersey, New Hampshire, New York, Ohio, Oregon, Pennsylvania, Texas, Utah, Virginia, Washington, and Wisconsin.[3]
Innerwell was founded by Lisa Kennedy, who serves as CEO, with the explicit mission to democratize access to psychedelic-assisted mental health treatment.[1] The company emerged at a pivotal moment when psychedelic medicine is gaining clinical validation and regulatory approval for treating conditions like depression, anxiety, PTSD, and trauma.[1][2]
The founding team recognized a critical gap: while ketamine-assisted psychotherapy has demonstrated clinical efficacy in office-based settings, no company had commercially scaled a true virtual KAP model that preserved the therapeutic rigor of in-person treatment.[4] This insight drove Innerwell's development of an integrated platform that mirrors the gold-standard office-based model while leveraging telehealth's accessibility and cost advantages.
Innerwell operates at the intersection of three converging trends: the psychedelic medicine renaissance, the telehealth acceleration, and the mental health crisis.
The timing is critical. Ketamine has FDA approval for treatment-resistant depression, and psilocybin and MDMA are advancing through late-stage clinical trials for PTSD and depression.[2] Simultaneously, the post-pandemic mental health crisis has created urgent demand for scalable, accessible treatment options. Innerwell captures this moment by building infrastructure that can absorb and distribute these emerging therapies at scale.
The company also influences the broader ecosystem by establishing operational standards for virtual psychedelic-assisted care—a category that barely existed two years ago. By demonstrating that rigorous, evidence-based KAP can be delivered virtually, Innerwell creates a template for other telehealth platforms and traditional mental health providers to follow, potentially accelerating mainstream adoption of psychedelic medicine.
Innerwell is positioned to become a category leader in virtual psychedelic-assisted therapy, but success depends on three factors: (1) clinical outcomes that match or exceed office-based KAP, (2) insurance reimbursement expansion beyond current partnerships, and (3) regulatory clarity as psilocybin and MDMA move toward approval.
The company's stated roadmap includes expanding beyond ketamine to psilocybin and MDMA-assisted therapy, both at-home and in-person.[2] This suggests ambitions to become a comprehensive psychedelic medicine platform rather than a single-indication telehealth service.
The broader question: Can Innerwell scale clinical excellence in a virtual setting while maintaining the therapeutic relationships that make psychedelic-assisted therapy effective? If yes, the company could reshape how millions of Americans access mental health treatment. If execution falters, it risks becoming one of many telehealth platforms competing on price rather than outcomes—a far less defensible position in a capital-intensive, clinically demanding space.
